Wills Eye

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Wills Eye sits in the top decile of US sponsors by registered trial count (#338 of 15,742 sponsors by registered trial count).

59 total trials 2 currently recruiting 52 completed early-phase tilt top decile by trial count

Wills Eye: 59 sponsored US clinical trials, 2 recruiting.

Wills Eye sponsors 59 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 52 completed. 5 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glaucoma, with 5 trials.

Top-decile sponsor footprint

Wills Eye ranks in the top decile of sponsors by registered trial count (#338 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 72/100

52 of 56 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

59 total, page 1 of 2

RECRUITING NA

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

NCT03675412

RECRUITING

Novel Glaucoma Diagnostics

NCT00286637

ACTIVE NOT RECRUITING Phase 2

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT05660447

COMPLETED NA

Evaluating Home Testing Devices for the Management of Glaucoma

NCT05325996

COMPLETED Phase 4

Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.

NCT06130384

TERMINATED NA

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

NCT04784234

COMPLETED NA

visuALL Field Analyzer (vFA) Compared to Standard Humphrey Automated Perimetry

NCT03804684

COMPLETED NA

Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment

NCT03365778

COMPLETED Phase 4

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study

NCT03323164

COMPLETED NA

Handheld Vibrator Versus Topical Eye Drops as Anesthesia for Intravitreal Injections

NCT03079713

COMPLETED Phase 2

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

NCT03034772

COMPLETED NA

30g vs 33g Needle for Intravitreal Injections

NCT03038048

COMPLETED NA

Patient Comfort Using Green vs. Yellow Pan Retinal Photocoagulation

NCT02995629

TERMINATED NA

Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane

NCT02995746

COMPLETED

Social Worker in an Eye-Care Service

NCT03304535

COMPLETED NA

Using a Type of Blue Dye to Observe Bleb Function During Cataract Surgery

NCT02526706

COMPLETED

Comparing Rates of Glaucoma in Professional Wind Versus Non-Wind Instrument Players

NCT02612571

COMPLETED

Interest in Electronic Applications for Patients With Glaucoma

NCT02659709

COMPLETED

Factors Influencing Patient Satisfaction in a Glaucoma Population

NCT02628327

COMPLETED NA

27-gauge Vitrectomy Wound Integrity: a Prospective, Randomized Trial Comparing Angled Versus Straight Entry

NCT02836210

COMPLETED Phase 2

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

NCT02571972

COMPLETED NA

A Proposed Intervention to Decrease Resident-Performed Cataract Surgery Cancellation

NCT02621840

COMPLETED NA

Normative Database for Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG)

NCT02609204

COMPLETED NA

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

NCT02390245

COMPLETED NA

Comparison Study of Glaucoma Eye Care Follow-Up Adherence in a High Risk Population

NCT02347670

COMPLETED NA

Does Using a Low Vision Aid Device Improve Quality of Life in Glaucoma Patients?

NCT02526680

COMPLETED NA

How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?

NCT02627352

COMPLETED NA

Eplerenone for the Treatment of Central Serous Chorioretinopathy

NCT01990677

COMPLETED NA

Improving Follow-Up Adherence in a Primary Eye Care Setting

NCT02001129

COMPLETED

Comparing the Effect of the Water Drinking Test on Intraocular Pressure

NCT02001155

COMPLETED NA

Electric Stimulation of the Eye to Improve Vision After Trauma

NCT02019927

COMPLETED NA

Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.

NCT01860586

COMPLETED Phase 2

The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy

NCT01710332

COMPLETED NA

Overcoming Barriers in Vision Care Utilization of African Americans With Diabetes

NCT01744132

COMPLETED

Building a Database of Results From People Without Eye Problems

NCT02627339

COMPLETED NA

Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration

NCT01653184

TERMINATED Phase 1

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

NCT01533376

COMPLETED

Comparison of Gonioscopy With Cirrus and Visante

NCT01895686

COMPLETED NA

How Has Glaucoma Affected Your Quality of Life?

NCT01476644

COMPLETED NA

How Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?

NCT02622178

COMPLETED Phase 4

Isotretinoin for Proliferative Vitreoretinopathy

NCT01445028

COMPLETED NA

Confronting Unequal Eye Care in Pennsylvania

NCT01179555

COMPLETED NA

Does Glaucoma Cause Loss of Brain Function?

NCT01303939

TERMINATED NA

Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube

NCT01301378

COMPLETED NA

Water Drinking Test in Patients With Occludable Angle

NCT02613533

COMPLETED NA

Spaeth/Richman Contrast Sensitivity Test

NCT01300949

COMPLETED Phase 2

Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?

NCT00853905

COMPLETED Phase 2

Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

NCT00853073

COMPLETED NA

A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma

NCT00857519

COMPLETED Phase 4

How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?

NCT00798694

Page 1 of 2 Next →

What is open in the Wills Eye pipeline

2 recruiting of 59 indexed (3% open); 52 completed (88%).

Phase mix: 5 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Glaucoma (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Wills Eye: open-pipeline peers nationwide

Peers matched on 59 registered trials and 3% open enrollment, not the therapeutic-area sidebar.

Wills Eye sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200 0%5%10%15%20%25% Total trials Recruiting share Wills EyeClinical Nutrition Research Center, Illinois Institute of TechnologyUnited States Army Research Institute of Environmental MedicineUniversity of GeorgiaHenry M. Jackson Foundation for the Advancement of Military MedicineSCRI Development InnovationsBiotronikCharles Drew University of Medicine and ScienceKyntra Bio
Wills Eye sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wills Eye sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 59 trials (± recruiting share)

Sponsors near 3% open enrollment (± trial volume)

What to do with this Wills Eye page

59 registered trials is a research-attention snapshot, not an endorsement of Wills Eye or any single study.

  • 2 of Wills Eye's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Glaucoma is the condition Wills Eye studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glaucoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Wills Eye pipeline card: 59 registered trials from official public datasets.Report a data error.